Clinical trial NCT02603627: Prevalence of COPD in Our Lung Cancer Population, Compared to Controls
Official title: Cross-sectional Study to Compare the Prevalence of Chronic Obstructive Pulmonary Disease (COPD) in Patients Newly Diagnosed With Lung Cancer, Compared to Controls
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COPD
Lung Cancer
Smoking
Lead sponsor: Guy's and St Thomas' NHS Foundation Trust
Sponsor class: OTHER
First posted: 2015-11-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruited from the multidisciplinary lung cancer clinic at Guy's Hospital.

Controls will be recruited from the smoking cessation clinic at Guy's and St Thomas' NHS Foundation Trust.

Brief summary: This study will investigate the prevalence of chronic obstructive pulmonary disease (COPD) in patients who are newly diagnosed with lung cancer and compare it to the prevalence of COPD in controls recruited from a smoking cessation clinic.

Detailed description: Chronic obstructive pulmonary disease (COPD) is a breathing problem that some people develop. Usually it is caused by smoking. Damage to the lungs means that patients are at risk of more chest infections and are unable to exercise like healthy individuals. They may also have a long-standing cough.

COPD is diagnosed by testing lung function, usually using a small device called a spirometer.

COPD is becoming a better understood condition. It is known that the lungs of patients with COPD are sometimes inflamed. This is important because inflammation is associated with some types of cancer, including lung cancer.

The investigators are interested in whether COPD puts people at higher risk of lung cancer. They would like to find out how common COPD is in patients who have lung cancer. The investigators would also like to find out how common COPD is in patients who are not known to have lung cancer (comparison group). This will help them interpret their results better as investigators will be able to compare the two groups.

Eligibility criteria: Inclusion Criteria:

* Informed consent
* Aged over 18
* Lung cancer group: new diagnosis of lung cancer, with spirometry results available Control group: spirometry result available or obtained

Exclusion Criteria:

* Patient refusal
* Age under 18
* Control group: pre-existing lung cancer

Primary outcomes:
measure: Prevalence of COPD in lung cancer compared to controls, using spirometry to diagnose COPD.
timeFrame: Up to nine months
Secondary outcomes:
measure: Comparison of the proportion of small cell tumours to non-small cell tumours in patients with lung cancer and COPD.
timeFrame: Up to nine months
measure: Comparison of the proportion of individuals with an emphysematous phenotype to the proportion of individuals with a bronchitic phenotype.
timeFrame: Up to nine months
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Guy's and St Thomas' NHS Foundation Trust
state: England
Study officials:
affiliation: King's Health Partners
name: Tariq Sethi, MBBS PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Guy's and St Thomas' NHS Foundation Trust
name: Anthony Dorr, MBBS PhD
role: PRINCIPAL_INVESTIGATOR
References: